Data / Form D filings / Objective Biotechnology, Inc.
Objective Biotechnology, Inc.: Form D filing
Objective Biotechnology, Inc., a biotechnology company in Minneapolis, MN, filed a Form D with the SEC in 2024. The latest, on November 26, 2024, reports $714,984 sold of a $1 million offering to 11 investors.
SpecStream is the live web data engine for teams and agents. It reads every Form D on SEC EDGAR the day it is filed, and this page is that reading. Ask for your own cut (a state, an industry, a size) and new filings arrive in your sheet, CRM, Slack or agent as they land.
Company details from the filing
- Address
- 126 N. THIRD STREET, SUITE 540, Minneapolis, MN, 55401
- Phone
- (507) 321-9119
- Industry
- Biotechnology
- Entity type
- Corporation
- Incorporated in
- Delaware
- Year incorporated
- 2023
- Revenue range
- Decline to Disclose
- Exemptions claimed
- Rule 506(b)
- SEC identifier (CIK)
- 2045193
Form D filings
| Filed | Type | Offering | Sold | Remaining | Investors | First sale | Filing |
|---|---|---|---|---|---|---|---|
| Nov 26, 2024 | New notice | $1,000,000 | $714,984 | $285,016 | 11 | Nov 20, 2024 | sec.gov |
Executive officers and directors named in the filing
| Name | Role | Note in the filing |
|---|---|---|
| James Grabau | Executive Officer | |
| Daniel Surinach | Executive Officer, Director | |
| Amey Joshi | Executive Officer, Director | |
| Suhasa Kodandaramaiah | Executive Officer, Director | |
| Andrew Alegria | Executive Officer, Director | |
| Daryl Gohl | Executive Officer, Director |
Other biotechnology companies in Minnesota that filed recently
- Medical 21, Inc. $550,000 · Oct 23, 2026
- InSitu Biologics, Inc. $1.3 million · Oct 14, 2026
- Evia Bio, Inc. $5.5 million · Sep 28, 2026
- EyeMacular Regeneration, Inc. $2.9 million · Sep 25, 2026
- ProEncia Biotechnology Inc. $1.5 million · Aug 26, 2026
Every Form D from the week of Nov 25, 2024 · All recent filings in Minnesota · All recent Biotechnology filings
Read from SEC EDGAR. Amount sold is what Objective Biotechnology, Inc. reported on the day it filed; on an offering that is still open, a later amendment can raise it. Free to reuse with credit to SpecStream under CC BY 4.0.